Safety and efficacy of transdermal buprenorphine and transdermal fentanyl in the treatment of neuropathic pain in AIDS patients

Minerva Anestesiologica

Volumn 79, Issue 8, 2013, Pages 871-883

  Canneti, A ^a   Luzi, M ^a   Di Marco, P ^a   Cannata, F ^a   Pasqualitto, F ^a   Spinoglio, A ^a   Reale, C ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Acquired immunodeficiency syndrome; Buprenorphine; Fentanyl; Pain

Indexed keywords

BUPRENORPHINE; CD4 ANTIGEN; FENTANYL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MACROGOL; METOCLOPRAMIDE; MORPHINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS PATIENT; ARTICLE; CHRONIC PAIN; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONSTIPATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KARNOFSKY PERFORMANCE STATUS; MALE; NEUROPATHIC PAIN; NEUROPATHIC PAIN SCALE; PAIN ASSESSMENT; RATING SCALE; TREATMENT DURATION; VISUAL ANALOG SCALE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; CD4-CD8 RATIO; FEMALE; FENTANYL; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEURALGIA; PAIN MEASUREMENT; PATIENT SATISFACTION; TRANSDERMAL PATCH; TREATMENT OUTCOME;

EID: 84887059010     PISSN: 03759393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Barasa SS. True story about HIV: theory of viral sequestration and reserve infection. HIV AIDS (Auckl) 2011;3:125-33.
2. Supplemento del notiziario dell' Istituto Superiore di Sanità. Aggiornamento delle nuove diagnosi di infezione da HIV al 31 Dicembre 2009 e dei casi di AIDS in Italia al 31 Dicembre 2010; Vol. 24. Num. 5. Supplemento 1-2011.
3. Tagliati M, Grinnel J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Arch Neurol 1999;56:84-9. (Pubitemid 29046913)
4. Head KA. Peripheral neuropathy: pathogenic mechanism and alternative therapies. Alter Med Rev 2006;11:294-329. (Pubitemid 46037130)
5. Mercadante S. Il dolore. Valutazione, diagnosi e trattamento. Il dolore nel paziente con infezione da HIV/AIDS. New York: Masson Publishing; 2006. p. 181-5.
6. Finley MJ, Happel CM, Kaminsky DE, Rogers TJ. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 2008;252:146-54.
7. Planjar-Prvan m, Bielen I, Baraba R, Buljan R. Pathophysiologic basis of the treatment of neurogenic pain. Acta Med Croatica 2004;58:197-205.
8. Apolone G, Mosconi P, Quattrociocchi L, Gianicolo EAL, Groth N, Ware JE. Questionario sullo stato di salute SF-12. Guerini e Associati 2005;1-85.
9. Pain Syndrome and Perifeal Neuropathy Guide for HIV/AIDS Clinical Care, HRSA HIV/AIDS Bureau. 2012; 1-7.
10. Krashin DL, Merril JO, Trescot AM. Oppioid in the management of HIV - Related Pain. Pain Physician 2012;15:157-68.
11. Martucci C, Franchi S, Lattuada D, Panerai AE, Sacerdote P. Differential involvement of RelB in morphine-induced modulation of Chemotaxis, NO, and cytokine production in murine macrophages and lymphocytes. Journal of Leucocyte Biology 2007;81 344-54. (Pubitemid 46021285)
12. Wang J, Barke RA, Charboneau R, Loh HH, Roy S. Morphine negatively regulates interferon-gamma promoter activity in activated murine T cells through two distinct cyclic AMP-dependent pathways. J Biol Chem 2003;278:37622-31. (Pubitemid 37175285)
13. Vallejo R, de Leon Casasola O, Benyamin R. Opioid therapy and immunosuppression: a rewiew. Am J Ther 2004;11:354-65.
14. Sacerdote P. Opioids and the immune system. Paliat Med 2006;20(Suppl 1):s9-15.
15. Limiroli E, Gaspani L, Panerai AE, Sacerdote P. Differential morphine tolerance development in the modulation of macrophage cytokine production in mice. J Leukoc Biol 2002;72:43-8.
16. Börner C, Warnick B, Smida M, Hartig R, Lindquist JA, Schraven B et al. Mechanism of opioid-mediated inhibition of human T cell receptor signalling. J Immunol 2009;183:882-9.
17. Gomez-Florez R, Weber RJ. Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat. Immunopharmacology 2000;48:145-56. (Pubitemid 30608671)
18. D'Elia M, Pateunaude J, Hamelin C, Garrel DR, Bernier J. No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters. ClinImmunol 2003;109:179-87. (Pubitemid 37338624)
19. Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int J ClinPract Suppl 2003;(133):9-14; discussion 23-4.
20. Likar R, Griessinger N, Sadjak A, Sitti R. Transdermal buprenorphine for treatment of chronic tumor and no tumor pain. Wien Med Wochenschr 2003;153:317-22. (Pubitemid 36961339)
21. Penza P, Campanella A, Martini A, Melli G, Lombardi R, Camozzi F et al. Short and intermediate-term efficacy of buprenorphine Tds in chronic painful neuropathies. J PeripherNerv Syst 2008;13:283-8.
22. Wang X, Ye L, Zhou Y, Liu MQ, Zhou DJ, Ho WZ. Inhibition of anti HIV microRNA expression: a mechanism for opioid-mediated enhancement of HIV infection of monocytes. Am J Pathol 2011;178:41-7.
23. Zaki PA, Keith DE JR, Brine GA, Carrol FI, Evans CJ. Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation? J Pharmacol Exp Ther 2000;292:1127-34. (Pubitemid 30136610)